A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
Completed · Phase 1 · NCT05868356
Conditions: Healthy Adults
At a glance
- Research payments reported, 2025
- $65,414
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- Treatment A (drug), Treatment B (drug)
- Dates
- Started 2023-06-01; completion 2023-08-07
- Results posted
- Not yet
A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult Subjects
From ClinicalTrials.gov, last updated 2024-03-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mirati Therapeutics, Inc. reported $65,414 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research $65,414
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.